<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04250181</url>
  </required_header>
  <id_info>
    <org_study_id>HPvSP-AF ablation</org_study_id>
    <nct_id>NCT04250181</nct_id>
  </id_info>
  <brief_title>High Power vs Standard Power RF Ablation of Atrial Fibrillation in Conscious Patients</brief_title>
  <acronym>HPvSP-AF</acronym>
  <official_title>HPvSP-AF Trail: Is High RF Energy Ablation of Atrial Fibrillation Fast, Safe, Less Painful and Effective - a Propensity Score Matched Analysis of 30/25W, 40W and 50W RF Energy Settings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Lublin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Lublin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      High RF energy ablation of atrial fibrillation is fast, safe, less painful and effective
      procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation (AF) ablation is the most commonly performed radiofrequency (RF) ablation
      and is usually associated with a long procedural time and sensation of pain in conscious
      patients. Prolonged radiation exposure during the procedure puts the patient and the operator
      at risk of malignancy and genetic abnormalities. Complications such as asymptomatic cerebral
      lesions, tamponade, perforation, and also arrhythmia recurrence were associated with longer
      ablation time.

      High-power, shorter-duration radiofrequency ablation (HPSDRFA) appears to be a novel concept
      for atrial fibrillation (AF) but there are scarce data in conscious patients. The lesion side
      index (LSI) value has been associated with durability of pulmonary vein isolation (PVI)
      lesions.

      We hypothesised that HPSDRFA applications based on the lesion side index (LSI; its has been
      associated with durability of pulmonary vein isolation (PVI) lesions) which were not inferior
      to standard approach regarding safety and effectiveness with shorten procedure time and being
      less painful for a patient.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 15, 2019</start_date>
  <completion_date type="Actual">February 8, 2020</completion_date>
  <primary_completion_date type="Actual">January 20, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Procedure time:</measure>
    <time_frame>procedure</time_frame>
    <description>Total procedure time (needle to needle time).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left atrial dwelling time</measure>
    <time_frame>transeptal access to removal of a catheter and a sheath</time_frame>
    <description>time of left atrium instrumentation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Voltage mapping time</measure>
    <time_frame>procedure</time_frame>
    <description>time needed to perform 3D electroanatomical map and high density voltage mapping of left atrium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total RF time</measure>
    <time_frame>procedure</time_frame>
    <description>time of all performed radiofrequency (RF) applications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of RF applications</measure>
    <time_frame>procedure</time_frame>
    <description>number of all RF applications performed during a procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>X-Ray time</measure>
    <time_frame>procedure</time_frame>
    <description>the total time of fluoroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>12 months</time_frame>
    <description>both procedure-related complications and all complications in 12 moths follow-up as follows: Cardiac tamponade/perforation [yes/no], Stroke/TIA (Transient ischemic attack) [yes/no], Oesophageal injury (perforation/fistula) [yes/no], Death (procedural related, one year follow up) [yes/no], Stem pops [yes/no], Catheter char [yes/no], Phrenic nerve paralysis [yes/no], PV stenosis requiring intervention [yes/no], Gastrointestinal bleeding or gastrointestinal complaints [yes/no], Need for periprocedural pacemaker implantation [yes/no], Vascular access complication which required intervention [yes/no], Vascular access complication which not required intervention [yes/no],</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of stopped RF applications as a result of pain complained by a patient</measure>
    <time_frame>procedure</time_frame>
    <description>the surrogate for assessment of the painfulness of the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up-30s</measure>
    <time_frame>procedure</time_frame>
    <description>absence any arrhythmia recurrence (AR) defined as any documented recurrence of AF and/or atrial tachycardia (AT) and /or atrial flutter (AFL) lasting longer than 30 second</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Standard RF</arm_group_label>
    <description>ablation with RF power of 30 Watts (30W) and with 25 Watts (25W) on posterior wall</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High RF 40W (40 Watts)</arm_group_label>
    <description>ablation with RF power of 40 watts (40W)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High RF 50W (50 Watts)</arm_group_label>
    <description>ablation with RF power of 50 watts (50W)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>RF ablation of atrial fibrillation</intervention_name>
    <description>Comparison of standard, 40W and 50W RF energy setting for ablation of atrial fibrillation</description>
    <arm_group_label>High RF 40W (40 Watts)</arm_group_label>
    <arm_group_label>High RF 50W (50 Watts)</arm_group_label>
    <arm_group_label>Standard RF</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with atrial fibrillation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  symptomatic patients with non-valvular AF,

          -  aged:18-85, first procedure in left atrium,

          -  exclusion of thrombus in left atrium and left atrium appendage,

          -  left ventricle ejection fraction &gt;55%

        Exclusion Criteria:

          -  age below 18 or above 85 years,

          -  left ventricle ejection fraction&lt;55%,

          -  previous procedure in left atrium,

          -  valvular AF
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MACIEJ MACIEJ, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MEDICAL UNIVERSITY OF LUBLIN, POLAND</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Lublin</name>
      <address>
        <city>Lublin</city>
        <zip>20-091</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <results_reference>
    <citation>Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, Damiano RJ Jr, Davies DW, DiMarco J, Edgerton J, Ellenbogen K, Ezekowitz MD, Haines DE, Haissaguerre M, Hindricks G, Iesaka Y, Jackman W, Jalife J, Jais P, Kalman J, Keane D, Kim YH, Kirchhof P, Klein G, Kottkamp H, Kumagai K, Lindsay BD, Mansour M, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Nakagawa H, Natale A, Nattel S, Packer DL, Pappone C, Prystowsky E, Raviele A, Reddy V, Ruskin JN, Shemin RJ, Tsao HM, Wilber D. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace. 2012 Apr;14(4):528-606. doi: 10.1093/europace/eus027. Epub 2012 Mar 1.</citation>
    <PMID>22389422</PMID>
  </results_reference>
  <results_reference>
    <citation>Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castellá M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Alexandru Popescu B, Schotten U, Van Putte B, Vardas P. 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. Rev Esp Cardiol (Engl Ed). 2017 Jan;70(1):50. doi: 10.1016/j.rec.2016.11.033. English, Spanish. Erratum in: Rev Esp Cardiol (Engl Ed). 2017 Nov;70(11):1031.</citation>
    <PMID>28038729</PMID>
  </results_reference>
  <results_reference>
    <citation>Galeazzi M, Ficili S, Dottori S, Elian MA, Pasceri V, Venditti F, Russo M, Lavalle C, Pandozi A, Pandozi C, Santini M. Pain perception during esophageal warming due to radiofrequency catheter ablation in the left atrium. J Interv Card Electrophysiol. 2010 Mar;27(2):109-15. doi: 10.1007/s10840-009-9447-y. Epub 2009 Nov 27.</citation>
    <PMID>19943098</PMID>
  </results_reference>
  <results_reference>
    <citation>Aryana A, Heist EK, D'Avila A, Holmvang G, Chevalier J, Ruskin JN, Mansour MC. Pain and anatomical locations of radiofrequency ablation as predictors of esophageal temperature rise during pulmonary vein isolation. J Cardiovasc Electrophysiol. 2008 Jan;19(1):32-8. Epub 2007 Sep 24.</citation>
    <PMID>17900251</PMID>
  </results_reference>
  <results_reference>
    <citation>Patel PJ, Padanilam BJ. High-power short-duration ablation: Better, safer, and faster? J Cardiovasc Electrophysiol. 2018 Nov;29(11):1576-1577. doi: 10.1111/jce.13749. Epub 2018 Oct 25.</citation>
    <PMID>30357991</PMID>
  </results_reference>
  <results_reference>
    <citation>Winkle RA, Mohanty S, Patrawala RA, Mead RH, Kong MH, Engel G, Salcedo J, Trivedi CG, Gianni C, Jais P, Natale A, Day JD. Low complication rates using high power (45-50 W) for short duration for atrial fibrillation ablations. Heart Rhythm. 2019 Feb;16(2):165-169. doi: 10.1016/j.hrthm.2018.11.031.</citation>
    <PMID>30712645</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 29, 2020</study_first_submitted>
  <study_first_submitted_qc>January 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2020</study_first_posted>
  <last_update_submitted>February 14, 2020</last_update_submitted>
  <last_update_submitted_qc>February 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Lublin</investigator_affiliation>
    <investigator_full_name>Maciej Wójcik, MD, PhD</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation ablation</keyword>
  <keyword>high power radiofrequency ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

